Adjuvant Therapy in Early-Stage ER-Positive, HER2-Negative Invasive Breast Cancer

Share it with your friends Like

Thanks! Share it with your friends!


Dr. Hope Rugo shares her experience on the recommended treatment approach for ER-positive, HER2-negative breast cancer patients. She comments on what is the expected benefit of adjuvant chemotherapy and endocrine therapy in luminal breast cancers and mentions that one of the greatest challenges is to understand the heterogeneity of the tumor.

She also provides interesting comments on the use of criteria like tumor grade and size to select the patients for adjuvant chemotherapy as well as the usage of IHC markers such hormone receptors ER-positive, PR and Growth Factor Receptor HER2 to identify patients for chemotherapy.

Finally, she speaks about tools such Adjuvant! Online and Predict and debates if these tools could be used to select luminal breast cancer patients confidently for adjuvant chemotherapy.
Hope Rugo, MD, is the Clinical Professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology and Clinical Trials Education at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.


Write a comment